RCS - Physiomics PLC - Publication of article in Frontiers in Oncology

PhysiomicsAnnouncement

09/05/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230509:nRSI6689Ya&default-theme=true

RNS Number : 6689Y  Physiomics PLC  09 May 2023

9 May 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Publication of article in Frontiers in Oncology

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting
oncology drug development and personalised medicine solutions, is pleased to
announce the publication of an original article "Should personalised dosing
have a role in cancer treatment?" in a special edition of the journal
"Frontiers in Oncology" focused on the FDA's Project Optimus.  The full
article can be accessed via the following link:

https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Oncology&id=1154493
(https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Oncology&id=1154493)
.

 

Project Optimus has relevance to Physiomics both in its core consulting
business and its personalised oncology initiatives.  In core consulting,
Project Optimus encourages and some would say even mandates biotech and pharma
companies to fully utilise all available non-clinical and clinical data to
make informed decisions about clinical trial design and biologically effective
dose.  The Company believes that there is an increasing expectation that
companies meeting with the FDA should have utilised mathematical modelling in
support of clinical trial design and dosing decision making.  The Company has
first hand experience of this through the translational modelling work it has
completed for multiple small and medium sized clients in recent years.

 

Looking beyond drug development, the Company sees a clear implication of
Project Optimus on dosing of approved drugs in cancer.  The vast majority of
cancer drugs are still approved on a "one size fits all" basis with, at most,
adjustments in dosing being made to account for body weight or surface area of
individual patients.  The Company believes that the future direction of
cancer drug dosing will take into account its effect in each individual and we
believe that our personalised dosing tool is a clear step towards achieving
that goal.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUWUNROUUVRAR